Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease among 948,263 individuals ≥ 65 years of age: a Danish cohort study

Katrine Finderup Nielsen*, Lise Birk Nielsen, Frederikke Kristensen Lomholt, Sarah Kristine Nørgaard, Hans Christian Slotved, Tine Dalby, Kurt Fuursted, Charlotte Sværke Jørgensen, Palle Valentiner-Branth

*Corresponding author

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Abstract

This study aimed to estimate the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) against invasive pneumococcal disease (IPD) among individuals ≥ 65 years of age. We used Danish nationwide databases to obtain information on PPV23 vaccination, covariates, and IPD and linked data on an individual level using a unique personal identifier. A total of 948,263 individuals were included and followed between June 15, 2020, and September 18, 2021 (58.6% were vaccinated during follow-up). The adjusted vaccine effectiveness was 42% (95% confidence interval (CI): 9–63%) for all-serotype IPD and 58% (95% CI: 21–78%) for PPV23-serotype IPD, using no vaccination as the reference.

OriginalsprogEngelsk
TidsskriftEuropean Journal of Clinical Microbiology and Infectious Diseases
Vol/bind41
Udgave nummer12
Sider (fra-til)1473-1477
Antal sider5
ISSN0934-9723
DOI
StatusUdgivet - dec. 2022
Udgivet eksterntJa

Bibliografisk note

Publisher Copyright:
© 2022, The Author(s).

Citer dette